Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04517851 · ClinicalTrials.gov registry record · Phase 2
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
A Phase 2 study of Primary Myelofibrosis and Myelofibrosis Transformation in Essential Thrombocythemia, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04517851: Active Phase 2 study of Primary Myelofibrosis and Myelofibrosis Transformation in Essential Thrombocythemia, sponsored by M.D. Anderson Cancer Center.
NCT04517851 is a Phase 2 study of Primary Myelofibrosis and Myelofibrosis Transformation in Essential Thrombocythemia that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04517851, a Phase 2 study of Primary Myelofibrosis and Myelofibrosis Transformation in Essential Thrombocythemia, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell count and bone marrow function.
Primary Outcome
OR is defined as CR (complete response) +PR (partial response) + CI (clinical improvement), where CI includes clinical improvements in anemia, splenomegaly and/or symptoms. Will estimate the OR rate, along with the exact 95% confidence interval.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- BIOLOGICAL Elotuzumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What the registry record for NCT04517851 still lists
NCT04517851 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire Administration is the first listed.
NCT04517851 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04517851 about?
NCT04517851 is a clinical study titled "Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis". This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell count and bone marrow function.
What is the current status of trial NCT04517851?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-02-10. Estimated completion is 2027-12-31.
What conditions does trial NCT04517851 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase.
What interventions are being tested in trial NCT04517851?
The interventions under investigation include: Questionnaire Administration (OTHER), Elotuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04517851?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04517851 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04517851's enrollment target sits among peer trials
15 29th of 30 higher than 2 of 30 other Primary Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Canakinumab in Patients With Myelofibrosis
RECRUITING · Phase 2
-
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI